The pharmacy benefit manager SmithRx has announced that through a partnership with the Mark Cuban Cost Plus Drug Company, it will offer Yusimry, an adalimumab biosimilar, for less than 90% of the cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback